A Suggested Modification to FIGO Stage IV Epithelial Ovarian Cancer-Reference-Cited by-同舟云学术

A Suggested Modification to FIGO Stage IV Epithelial Ovarian Cancer

Published:2023-01-24 Issue:3 Volume:15 Page:706
ISSN:2072-6694
Container-title:Cancers
language:en
Short-container-title:Cancers

Author:

Métairie Marie¹,Benoit Louise¹²^ORCID,Koual Meriem¹²,Bentivegna Enrica¹,Wohrer Henri¹,Bolze Pierre-Adrien³^ORCID,Kerbage Yohan⁴,Raimond Emilie⁵,Akladios Cherif⁶,Carcopino Xavier⁷,Canlorbe Geoffroy⁸⁹¹⁰,Uzan Jennifer¹¹,Lavoué Vincent¹²^ORCID,Mimoun Camille¹³^ORCID,Huchon Cyrille¹³,Koskas Martin¹⁴,Costaz Hélène¹⁵,Margueritte François¹⁶^ORCID,Dabi Yohann¹⁷^ORCID,Touboul Cyril¹⁷,Bendifallah Sofiane¹⁷,Ouldamer Lobna¹⁸^ORCID,Delanoy Nicolas¹⁹^ORCID,Nguyen-Xuan Huyen-Thu¹,Bats Anne-Sophie¹²⁰²¹,Azaïs Henri¹²⁰²¹^ORCID

Affiliation:

1. AP-HP (Assistance Publique des Hôpitaux de Paris), Department of Gynaecological Oncological and Breast Surgery, Hôpital Européen Georges-Pompidou, 75015 Paris, France

2. INSERM UMR-S 1124, University of Paris Cité, Centre Universitaire des Saints-Pères, 75006 Paris, France

3. Department of Gynaecologic and Oncologic Surgery and Obstetrics, Lyon Sud University Hospital, Hospices Civils de Lyon, Université Lyon 1, 69002 Lyon, France

4. CHU Lille, Department of Gynaecologic Surgery, University Lille, 59000 Lille, France

5. Department of Obstetrics and Gynaecology, Institute Alix de Champagne University Hospital, 51100 Reims, France

6. Department of Gynaecology, Hôpitaux Universitaires de Strasbourg, 67200 Strasbourg, France

7. Department of Obstetrics and Gynaecology, Hôpital Nord, APHM, Aix-Marseille University (AMU), University Avignon, CNRS, IRD, IMBE, UMR 7263, 13397 Marseille, France

8. AP-HP (Assistance Publique des Hôpitaux de Paris), Department of Gynaecological and Breast Surgery and Oncology, Pitié-Salpêtrière, 75013 Paris, France

9. Centre de Recherche Saint-Antoine (CRSA), INSERM UMR_S_938, Cancer Biology and Therapeutics, Sorbonne University, 75012 Paris, France

10. University Institute of Cancer, Sorbonne University, 75013 Paris, France

11. Department of Obstetrics Gynecology and Reproductive Medicine, University Paris Est Créteil, Centre Hospitalier Intercommunal de Créteil, 94000 Créteil, France

12. Department of Gynaecological Surgery, INSERM U1085, équipe 8, CRLC Eugène Marquis, Université de Rennes 1, Hôpital Sud, CHU de Rennes, 35000 Rennes, France

13. Department of Gynaecological Oncological and Breast Surgery—Université de Paris, Hôpital Lariboisière, 75010 Paris, France

14. AP-HP (Assistance Publique des Hôpitaux de Paris), Division of Gynaecologic Oncology, Bichat University Hospital, 75018 Paris, France

15. Department of Surgical Oncology, Georges-François Leclerc Centre, 21000 Dijon, France

16. Department of Gynaecology, Centre Hospitalier Intercommunal de Poissy-Saint-Germain-en-laye, Site Hospitalier de Poissy, 78498 Poissy, France

17. AP-HP (Assistance Publique des Hôpitaux de Paris), Department of Gynaecology ans Obstetrics, Hôpital Tenon, 75020 Paris, France

18. Department of Gynaecology, Hôpital Universitaire de Tours, 37000 Tours, France

19. AP-HP (Assistance Publique des Hôpitaux de Paris), Department of Medical Oncology, Hôpital Européen Georges-Pompidou, 75015 Paris, France

20. INSERM UMR-S 1147, University of Paris Cité, Centre de Recherche des Cordeliers, 75006 Paris, France

21. Institut du Cancer Paris CARPEM, 75006 Paris, France

Abstract

International Federation of Gynecology and Obstetrics (FIGO) staging classification for stage IV epithelial ovarian cancer (EOC) separates stages IVA (pleural effusion) and IVB (parenchymal and/or extra-abdominal lymph node metastases). We aimed to evaluate its prognostic impact and to compare survival according to the initial metastatic location. We conducted a multicenter study between 2000 and 2020, including patients with a FIGO stage IV EOC. Primary endpoint was overall survival (OS). The secondary endpoints were progression-free survival (PFS) and recurrence rates. We included 307 patients: 98 (32%) had FIGO stage IVA and 209 (68%) had FIGO stage IVB. The median OS and PFS of stage IVA patients were significantly lower than those of stage IVB patients (31 versus 45 months (p = 0.02) and 18 versus 25 months (p = 0.01), respectively). Recurrence rate was higher in stage IVA than IVB patients (65% versus 47% (p = 0.004)). Initial pleural involvement was a poor prognostic factor with a median OS of 35 months versus 49 months for patients without initial pleural involvement (p = 0.024). Patients with FIGO stage IVA had a worse prognosis than patients with FIGO stage IVB EOC. Pleural involvement appears to be relevant for predicting survival. We suggest a modification of the current FIGO staging classification.

Publisher

MDPI AG

Subject

Cancer Research,Oncology

Link

https://www.mdpi.com/2072-6694/15/3/706/pdf

Reference31 articles.

1. 2014 FIGO Staging for Ovarian, Fallopian Tube and Peritoneal Cancer;Mutch;Gynecol. Oncol.,2014

2. Cancer of the Ovary, Fallopian Tube, and Peritoneum;Berek;Int. J. Gynecol. Obstet.,2018

3. Sites of Distant Metastases and Overall Survival in Ovarian Cancer: A Study of 1481 Patients;Deng;Gynecol. Oncol.,2018

4. For the Groupe de Recherche FRANCOGYN, Dabi, Y., Huchon, C., Ouldamer, L., Bendifallah, S., Collinet, P., Bricou, A., Daraï, E., Ballester, M., and Lavoue, V. (2020). Patients with Stage IV Epithelial Ovarian Cancer: Understanding the Determinants of Survival. J. Transl. Med., 18, 134.

5. Subtypes of Stage IV Ovarian Cancer; Response to Treatment and Patterns of Disease Recurrence;Jamieson;Gynecol. Oncol.,2017

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. miRNA Expression Profiles in Ovarian Endometriosis and Two Types of Ovarian Cancer—Endometriosis-Associated Ovarian Cancer and High-Grade Ovarian Cancer;International Journal of Molecular Sciences;2023-12-14

2. Nomogram incorporating log odds of positive lymph nodes improves prognostic prediction for ovarian serous carcinoma: a real-world retrospective cohort study;BMJ Open;2023-10